| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 100 | 0 | 70 | 0 | 1,000 |
| Sales Growth | unch | -100.00% | unch | -100.00% | unch |
| Net Income | -2,950 | -4,250 | -4,660 | -4,720 | -4,610 |
| Net Income Growth | +30.59% | +8.80% | +1.27% | -2.39% | +6.49% |
Lisata Therapeutics Inc (LSTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly known as Caladrius Biosciences Inc., is based in BASKING RIDGE, N.J.
Fiscal Year End Date: 12/31